Onxeo to Present at Biotech Showcase™ Annual Conference during JP Morgan Healthcare Conference

J.P. Morgan Healthcare Conference 2015

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX
Copenhagen: ONXEO), an innovative company specializing in the development of
orphan oncology drugs, today announced that Judith Greciet, CEO of Onxeo, will
be giving a corporate overview of Onxeo on Wednesday, January 14, 2015 at the
Biotech Showcase 2015 Conference which is being held in San Francisco, CA (USA).

With more than 1,500 investors and companies participating, the Biotech Showcase
is one of the largest annual international healthcare investor conferences and
runs parallel to the JP Morgan Healthcare Conference (San Francisco, January 12
-15, 2015).

The details of Onxeo’s presentation are as follows:

Event:  Biotech Showcase 2015 Conference
Date: Wednesday, January 14, 2015
Time:  3:30 p.m. (PST)
Location:  Room Hearst (4th floor) - Parc 55 Wyndham San Francisco Union Square
Hotel,  San Francisco

About Biotech Showcase™
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase
is an investor and partnering conference devoted to providing private and public
biotechnology and life sciences companies an opportunity to present to, and meet
with, investors and pharmaceutical executives during the course of one of the
industry’s largest annual healthcare investor conferences. Now in its seventh
year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62